Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.
about
Current perspectives on HIV-1 antiretroviral drug resistanceExposure to MIV-150 from a high-dose intravaginal ring results in limited emergence of drug resistance mutations in SHIV-RT infected rhesus macaquesEffects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors.Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors.DOCK 6: Impact of new features and current docking performance.Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase.Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitorsBasis for early and preferential selection of the E138K mutation in HIV-1 reverse transcriptase.The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.Prevalence of Transmitted Drug-Resistance Mutations and Polymorphisms in HIV-1 Reverse Transcriptase, Protease, and gp41 Sequences Among Recent Seroconverters in Southern Poland.In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.Structure-enhanced methods in the development of non-nucleoside inhibitors targeting HIV reverse transcriptase variants.Antiretroviral activity and safety of once-daily etravirine in treatment-naive HIV-infected adults: 48-week results.In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways.In vitro selection of HIV-1 CRF08_BC variants resistant to reverse transcriptase inhibitors.What do docking and QSAR tell us about the design of HIV-1 reverse transcriptase nonnucleoside inhibitors?Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection.Discovery of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the Tolerant Region I of NNIBP.A computational study for rational HIV-1 non-nucleoside Reverse Transcriptase inhibitor selection and discovery of novel allosteric pockets for inhibitor design.Structural basis for potent and broad inhibition of HIV-1 RT by thiophene[3,2-]pyrimidine non-nucleoside inhibitors
P2860
Q26852626-5126C0EE-0A28-4336-BCD3-1724FCE31C4FQ28540200-CBD6DD31-9A97-4B8B-A0AE-D5F8FC48EB38Q34058254-68D49FA4-596D-4CB7-A824-4139C41A615EQ35105844-8D5DD34E-354A-4D12-A50A-3E2DC3949FE4Q35748554-E0AE7ABE-7117-4DC8-B15B-281C90B9FE9CQ36290753-0770BD06-15C7-4CA8-8D78-CD771C5575F2Q36543845-CAE6ABDF-B009-4EA6-8D41-730C09DB0F84Q37263541-B72DF44E-998B-48BA-9DB4-B580902D1B5BQ37263786-BD0C8323-C535-46E3-971D-7010D2F9ECECQ37547275-DE5BFAC2-1717-415D-B8E9-49A46FC5CAC2Q37643256-2CC5CBF2-4F16-4425-9C9D-1B81A0A84D93Q37643598-396FC979-AB16-469A-96CD-6AE9EAF71689Q38620336-28D7F4D6-3F8B-4C87-9EEE-67187778A583Q41059063-64205058-3748-46B5-B437-1557B7662C9FQ41668874-87C7D75A-7723-45A6-A7B2-EE81B3C0A493Q41720036-D6E517E2-7C57-4734-8C08-6B0D5DA21BF4Q47136053-A95B01D9-00A7-4EE7-BE91-2324452C2711Q47301806-CE7E992C-272A-40F1-8E9C-5B3E01944028Q47575876-41A4893E-0994-4EE2-8FAB-C22F86E23E49Q50043498-28F98C46-60D3-404B-B19C-33223B9B32CBQ56531878-A5228BCC-2EAC-452B-A797-8A0221E39E61
P2860
Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Effect of mutations at positio ...... rs rilpivirine and etravirine.
@en
type
label
Effect of mutations at positio ...... rs rilpivirine and etravirine.
@en
prefLabel
Effect of mutations at positio ...... rs rilpivirine and etravirine.
@en
P2093
P2860
P356
P1476
Effect of mutations at positio ...... rs rilpivirine and etravirine.
@en
P2093
Eugene L Asahchop
Hong-Tao Xu
Mark A Wainberg
Matthew McCallum
Maureen Oliveira
Susan M Schader
Susan P Colby-Germinario
Yingshan Han
Yudong Quan
P2860
P304
P356
10.1128/AAC.00348-13
P407
P577
2013-04-22T00:00:00Z